Gabapentin Capsule
Product Images NDC 58118-3224

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 58118-3224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 400mg Capsules 30ct Blister Card (Gabapentin 100mg 100cap)

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

Gabapentin-equation (Gabapentin Equation)
This text provides a formula for estimating creatinine clearance. It involves multiplying the weight in kilograms by the serum creatinine level. For female patients, the calculated value should be further multiplied by 0.85.*
FDA Label Image

Structure (Gabapentin Fig 5)

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

Gabapentin-fig1 (Gabapentin Fig1)
This text provides information about a study involving a mean pain score, a 4-week dose titration period, and a 4-week fixed dose period. It includes details comparing the placebo group with the group taking Gabapentin at a dosage of 3600 mg/day. The data is related to pain assessments at baseline.*
FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

Gabapentin-fig2 (Gabapentin Fig2)
This text provides information on the Mean Pain Score in a study involving different doses of Gabapentin and a placebo over the course of several weeks. The study appears to have a Dose Titration Period and a Fixed Dose Period for each group. The Gabapentin doses mentioned are 1800 mg/day and 2400 mg/day.*
FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

Gabapentin-fig3 (Gabapentin Fig3)
This text provides information on the proportion of responders in controlled studies on postherpetic neuralgia (PHN) treated with different doses of GBP (Gabapentin) compared to placebo (PBO). The results suggest that a higher dose of GBP (3600) had a response rate of 29%, compared to only 12% for a lower dose of 1800 and 14% for 2400. The statistical significance of these findings is also indicated (#p<0.001).*
FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.